Il-Yang Pharm. Co., Ltd.
Clinical trials sponsored by Il-Yang Pharm. Co., Ltd., explained in plain language.
A pharmaceutical company developing and marketing prescription drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IY-828026 tested in healthy people for first time Results expected Mar 2027 (estimated)
- Can a new pill rescue patients when standard leukemia drugs stop working? Results expected Jun 2027 (estimated)
- Can a lower dose of a leukemia drug keep the disease in check? Results expected Jul 2027 (estimated)
-
Can a new pill rescue patients when standard leukemia drugs stop working?
Disease control Recruiting nowThis phase 3 trial tests the drug radotinib in adults with chronic-phase chronic myeloid leukemia (CML) who have not responded to or could not tolerate earlier treatments such as imatinib. Participants take radotinib twice daily, and researchers measure how well it reduces leukem…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IY-828026 tested in healthy people for first time
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called IY-828026 in 86 healthy adults aged 19 to 50. Participants receive either the drug or a placebo to see how the body processes it and if any side effects occur. The goal is to gather important safety and dosing informati…
Phase 1 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC